Carboplatin occupies a defined place in systemic cancer care, but that place depends on the malignancy and treatment setting. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. Forms DNA cross-links that interfere with replication and transcription. Its classification is Chemotherapy; Platinum-Based Chemotherapy, and the database links it with Ovarian; NSCLC; Breast; Head and Neck. The listed indications are Ovarian/fallopian tube/peritoneal cancer; NSCLC; breast cancer; head and neck and other solid tumors. Treatment examples include CarboTaxol; TCH/TCHP; carboplatin + pemetrexed; carboplatin + gemcitabine; ovarian platinum regimens. These regimens illustrate the practical context in which the medicine is used and, where applicable, the partners that complement its pharmacologic effect. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. Particular attention should be given to any biomarker, receptor expression, mutation, treatment-line, or prior-therapy requirement explicitly included in the indication field. Such details can determine whether a cancer diagnosis actually matches the documented use. The drug’s class should be considered alongside its individual mechanism, since agents within the same broad category may differ in target specificity and clinical positioning. Current product information should be reviewed because regulatory status and preferred combinations may evolve.